12 Results

People

  1. Batlevi
    Batlevi
  2. Hamlin
    Hamlin
  3. Horwitz
    Horwitz
  4. Intlekofer
    Intlekofer
  5. Matasar
    Matasar
  6. Noy
    Noy
  7. Palomba
    Palomba
  8. Zelenetz
    Zelenetz
  9. Kumar
    Kumar
  10. Moskowitz
    Moskowitz

Groups

  1. Center for Hematologic Malignancies (12)
  2. Department of Medicine (12)
  3. GSK Faculty (12)
  4. Hematologic Malignancies Research (12)
  5. Hematologic Malignancies, Division of (12)
  6. Human Oncology and Pathogenesis Program (12)
  7. Lymphoma (12)
  8. Population Sciences Research Program (12)
  9. Survivorship Research (12)
  10. Epidemiology and Biostatistics (9)
  1. "Hematologic Malignancies Research"
  2. "Center for Hematologic Malignancies"
  3. "Maria Palomba"
  4. "David Straus"
  5. "Blood"
Formats
  1. Meeting Abstract (12)
Groups
  1. Center for Hematologic Malignancies (12)
  2. Department of Medicine (12)
  3. GSK Faculty (12)
  4. Hematologic Malignancies Research (12)
  5. Hematologic Malignancies, Division of (12)
  6. Human Oncology and Pathogenesis Program (12)

More Groups

People
  1. Andrew Intlekofer (12)
  2. Andrew Zelenetz (12)
  3. Ariela Noy (12)
  4. Connie Batlevi (12)
  5. David Straus (12)
  6. Maria Palomba (12)

More People

Years
  1. 2022 (3)
  2. 2020 (2)
  3. 2019 (2)
  4. 2017 (2)
  5. 2016 (2)
  6. 2015 (1)
Publications
  1. Blood (12)
Publishers
  1. American Society of Hematology (12)

Results (12)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Characterization of a large cohort of patients with nodal marginal zone lymphoma shows prolonged survival, time-to-treatment, and time-to-transformation
    Meeting Abstract

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Favorable outcomes among patients with T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era
    Meeting Abstract

    Robin, E. T.; Drill, E.; Batlevi, C. L.; Caron, P.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; Joffe, E.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Retrospective analysis of gemcitabine and oxaliplatin (GemOx)-based treatment in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
    Meeting Abstract

    Schade, J. R.; Kim, C.; Drill, E.; Qiu, A.; Batlevi, C. L.; Caron, P.; Colbourn, D. S.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Genomic characteristics clinical phenotype and disease course of TP53 mutated diffuse large B cell lymphoma at diagnosis and relapse
    Meeting Abstract

    Joffe, E.; Batlevi, C. L.; Intlekofer, A. M.; Zelenetz, A. D.; Moskowitz, C. H.; Palomba, M. L.; Noy, A.; Straus, D. J.; Portlock, C. S.; Gerecitano, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Impact of PET staging of follicular lymphoma on treatment outcomes and prognosis
    Meeting Abstract

    Alperovich, A.; Batlevi, C. L.; Intlekofer, A. M.; Moskowitz, C. H.; Horwitz, S. M.; Zelenetz, A. D.; Palomba, M. L.; Moskowitz, A. J.; Gerecitano, J.; Hamlin, P. A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Outcomes of follicular lymphoma patients by dynamic FLIPI at diagnosis and initial treatment in the post-rituximab era
    Meeting Abstract

    Batlevi, C.; Alperovich, A.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save